Marimed (MRMD) Receivables (2011 - 2026)

Marimed (MRMD) has 15 years of Receivables data on file, last reported at $9.4 million in Q1 2026.

• Receivables for Q1 2026 came in at $9.4 million, up 2.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.4 million (up 2.8% YoY), and the FY2025 annual result was $9.1 million, up 4.26% from the prior year.
• Receivables advanced to $9.4 million in Q1 2026 per MRMD's latest filing, from $9.1 million in the prior quarter.
• Over five years, Receivables peaked at $9.4 million in Q1 2026 and troughed at $4.2 million in Q4 2022.
• A 5-year average of $7.2 million and a median of $7.6 million in 2024 frame the typical range for Receivables.
• On a YoY basis, Receivables climbed as much as 74.49% in 2023 and fell as far as 48.2% in 2023.
• A 5-year view of Receivables shows it stood at $4.2 million in 2022, then jumped by 74.49% to $7.3 million in 2023, then advanced by 19.69% to $8.7 million in 2024, then increased by 4.26% to $9.1 million in 2025, then rose by 3.57% to $9.4 million in 2026.
• Business Quant data shows MRMD's Receivables at $9.4 million in Q1 2026, $9.1 million in Q4 2025, and $8.0 million in Q3 2025.